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Electrochemical Skin Conductance
Correlates with Skin Nerve Fiber
Density
Peter Novak*
Autonomic Laboratory, Department of Neurology, Brigham and Women’s Faulkner Hospital, Harvard Medical School,
Boston, MA, USA
Purpose: Electrochemical skin conductance (ESC) using reverse iontophoresis and
chronoamperometry has been used to evaluate abnormal function of small fibers. How
ESC correlates with loss of small fibers in skin is unclear.
Methods: This was a prospective, blinded study. The primary outcome measure was
the correlation between ESC at the feet and results of skin biopsies including epidermal
nerve fiber density (ENFD) and sweat gland nerve fiber density (SGNFD) at the distal leg.
ESC, ENFD, and SGNFD data were normalized by adjusting for weight. The secondary
outcome measures were the correlation between ESC and the following variables:
quantitative sudomotor axon reflex test (QSART) and symptom scales (neuropathy, pain
and autonomic).
Results: Eighty-one patients (mean ± sd): age = 53.3 ± 17.3, men/women = 25/56
were enrolled in the study. ESC was reduced in subjects with abnormally low ENFD
(ENFD normal/abnormal, ESC = 1.17 ± 0.27/0.87 ± 0.34 µSiemens/kg, p < 0.0008)
and abnormally low SGNFD (SGNFD normal/abnormal ESC = 1.09 ± 0.34/0.78 ± 0.3
µSiemens/kg, p < 0.0003). ESC correlated with ENFD (ρ = 0.73, p = 0.0001) and
SGNFD (ρ = 0.64, p = 0.0001). ESC did not correlate with symptom scales.
Conclusion: ESC is diminished in subjects who have a reduced number of small fibers
in the skin and the ESC reduction is proportional to ENFD and SGNFD. ESC can be
useful in detecting loss of small nerve fibers.
Keywords: electrochemical skin conductance, sweat gland nerve fiber density, small fiber neuropathy, skin biopsy,
epidermal nerve fiber density
INTRODUCTION
Small fiber neuropathy (SFN) is common, affecting millions of people worldwide, and may be
associated with considerable disability (England et al., 2009; Lauria et al., 2010; Hovaguimian
and Gibbons, 2011; Hoeijmakers et al., 2012). Small nerve fibers, thinly myelinated Aδ-fibers
and unmyelinated C-fibers, can be separated into autonomic (efferent) or sensory (afferent).
Abbreviations: ESC, electrochemical skin conductance; ENFD, epidermal nerve fiber density; SGNFD, sweat gland nerve
fiber density; HbA1c, Hemoglobin A1c; QSART, quantitative sudomotor axon reflex test; SFN, small fiber neuropathy; TSH,
thyroid stimulating hormone.
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Their dysfunction can result in dysautonomia due to autonomic
SFN, sensory symptoms due to sensory SFN, or a combination
of both due to mixed sensory and small fiber SFN. Mixed
SFN is the most common form (Novak et al., 2001; Devigili
et al., 2008; Hovaguimian and Gibbons, 2011). Idiopathic SFN,
in which no cause can be identified, represents about 50% of
all SFN cases. The remaining secondary SFNs are associated
with multiple disorders including impaired glucose tolerance,
metabolic syndrome, thyroid dysfunction, sarcoidosis, vitamin
B12 deficiency, HIV, autoimmune syndromes, neurotoxic
medications including chemotherapeutic and antiretroviral
agents, celiac disease, paraneoplastic syndromes, alcohol abuse,
elevated triglycerides and paraproteinemias (England et al.,
2009; Lauria et al., 2010; Hovaguimian and Gibbons, 2011;
Hoeijmakers et al., 2012).
Although there is wide heterogeneity of SFN causes, the
available diagnostic tools detect either abnormal nerve function
(functional methods) or loss of axons (morphological methods),
irrespective of the underlying etiology. The morphological
methods include skin biopsies for assessment of sensory fibers
using epidermal nerve fiber density (ENFD) and sudomotor
fibers using sweat gland nerve fiber density (SGNFD). Among the
objective functional tests, the quantitative sudomotor axon reflex
test (QSART) evaluating postganglionic sudomotor function
is most widely used (Hovaguimian and Gibbons, 2011). A
recent addition is the measurement of the electrochemical skin
conductance (ESC) using Sudoscan technology (Impeto Medical,
Paris, France) (Casellini et al., 2013; Smith et al., 2014). The
Sudoscan device applies a small electrical stimulus to the skin
of the hands and palms; ESC is the derivative current produced
by sweat chloride ions (reverse iontophoresis) in response to
the applied stimulus, and has been found to be useful in the
diagnosis of diabetic and non-diabetic SFN (Casellini et al., 2013;
Smith et al., 2014). Distinct advantages of ESC are safety, ease
to use, speed and its noninvasive character. Reduced ESC may
reflect loss of small fibers; however, the direct comparison of
ESC with underlying pathology is lacking. In this study, a direct
functional-pathological correlation was performed where ESC
was compared to ENFD and SGNFD.
METHODS
Study Design
This was a prospective, blinded study. The study was approved by
the Institutional Review Board of the University of Massachusetts
Medical School and all subjects signed an informed consent.
Participants
The study participants included subjects who were referred
for evaluation of SFN to the tertiary care setting at the
University of Massachusetts Medical School, Autonomic
Laboratory in 2015. Recruitment was based on completing
the SFN evaluations. Inclusion criteria were patients older
than 17 years who completed evaluation for SFN at the
autonomic laboratory, had available electronic medical records
and provided informed consent. Electronic records were
reviewed for secondary causes of loss of small fibers including
diabetes, borderline diabetes, large fiber neuropathy, Parkinson’s
disease, atypical parkinsonism, known history of heavy alcohol
exposure, B12 deficiency, folate deficiency, thyroid disease,
hepatitis C, HIV infection, exposure to chemotherapy, use of
neurotoxic medication, cancer, any comorbid condition or
use of medication reported to be associated with small fiber
neuropathy. Hemoglobin A1c (HbA1c), B12, folate, and TSH
levels were also collected for further analysis.
Patient’s records were also reviewed for presence and
character of neuropathic pain (spontaneous, evoked, burning,
aching, stabbing, allodynic), numbness, tingling or pins and
needles sensation as well as distribution of sensory symptoms
(length or non-length dependent). The records were screened
for autonomic symptoms including postural dizziness and
hypotension, sphincter problems, abnormal sweating, and
gastrointestinal symptoms. Neurological examinations were
reviewed to identify abnormalities in proprioceptive evaluation,
muscle strength or deep tendon reflexes that may indicate large
fiber involvement. Particular emphasis was placed on identifying
signs of SFN including pinprick and thermal sensory loss,
allodynia and hyperalgesia (Devigili et al., 2008).
Evaluation of Sensory and Autonomic
Symptoms
This evaluation was done at the autonomic laboratory as part of
the SFN evaluation. Sensory evaluations included self-report of
pain intensity using a 0 to 10 numerical rating scale (Cook et al.,
2013), the Neuropathy Pain Symptom Inventory (Bouhassira
et al., 2004) and the Neuropathy Total Symptom Score-6 (Bastyr
et al., 2005). Autonomic symptoms were assessed using the
Survey of Autonomic Symptoms (Zilliox et al., 2011).
Skin Biopsies
Skin biopsies were performed for assessment of ENFD and
SGNFD. Skin biopsies were performed according to the
recommended standards (McArthur et al., 1998; Lauria et al.,
2010). Briefly, two skin biopsy samples were obtained, one from
the proximal thigh 20 cm distal to the iliac spine and the other at
the calf (10 cm above the lateral malleolus) using a 3-mm circular
disposable punch tool. Samples were immediately transferred
into 2% paraformaldehyde-lysine-periodic acid fixative and
transported overnight to the laboratory using cold packs
to maintain cooling. Tissue processing was conducted at a
commercial laboratory (Therapath, New York, NY). Therapath
is a CLIA-certified laboratory and is accredited by the College
of American Pathologists. Samples were immunoperoxidase-
stained for the pan-axonal marker PGP 9.5. Linear ENFD
was determined using bright light microscopy according to
the guidelines of the European Federation of the Neurological
Societies (Lauria et al., 2010). The density was calculated in at
least 3 sections as the number of nerve fibers per length of the
section (density/mm). Only single fibers crossing the dermal-
epidermal junctions were counted while secondary branching
was excluded from the analysis.
SGNFDwas determined using the same tissue sections stained
for PGP 9.5. Images of one or two sweat glands were captured
using an Olympus photomicrograph. The digital images were
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analyzed according to the method of (Gibbons et al., 2009).
All sweat gland nerve fiber counts were done by one board
certified neuropathologist who was blinded to the ESC results.
The SGNFD intra-rater variability was 8.4 ± 9.6% (mean and
standard deviation for 48 analyzed sweat glands during the last
1 year period) and the inter-rater variability was 10.2 ± 8.4%
for two observers within the same year (Dr. Hays, Therapath,
personal communication).
The limits of normality for ENFD at the thigh are 6.2/8.3
(men/women) fibers per millimeter of epidermal length as
determined by Therapath. The University of Massachusetts’
limits of normal ENFD (fibers per millimeter of epidermal
length) at the calf are equal to 9.5–0.075∗age for men and 11.1–
0.08∗age for women (Novak, 2015). The limits of normality for
SGN FD at the thigh and the calf are 37.8 and 36.5 fibers per
millimeter as determined by Therapath.
Autonomic Testing
Autonomic function testing was performed following established
standards that have been described in detail elsewhere (Novak,
2011, 2015). Cardiovascular reflex tests included deep breathing,
the Valsalva maneuver and tilt test. Postganglionic sudomotor
functions were assessed by QSART in the forearm, proximal leg,
distal leg, and foot, using the Q-Sweat machine (WR Medical
Electronics, Stillwater, MN).
Sudomotor Function Testing using ESC
ESC assessment was performed using the Sudoscan device
(ImpetoMedical, Paris, France) (Casellini et al., 2013; Smith et al.,
2014). Subjects were asked to place both palms and soles on large
area stainless-steel electrodes during the 3-min scan. The ESC
data acquisition was performed in the standing position. A low
direct current (DC) voltage (<4V) is applied incrementally to the
electrodes (chronoamperometry), generating a current (around
0.2 mA) proportional to the chloride ions extracted from the skin
(reverse iontophoresis). The ratio of the current generated by the
reaction of the chloride ions with the electrodes and the constant
DC stimulus applied is calculated for each foot and hand and
expressed as the ESC measured in microSiemens (µS).
Definition of SFN
Devigili et al. (2008) defined SFN by requiring the presence of
abnormalities in at least two of the following 3 examinations: (1)
clinical signs suggestive of SFN (pinprick or thermal sensory loss,
allodynia and hyperalgesia); (2) abnormal Quantitative Sensory
Testing (QST) and (3) reduced ENFD. The combination of
clinical signs and ENFD provides the highest diagnostic accuracy
(Devigili et al., 2008). These criteria use only sensorymarkers and
SFN also affects autonomic fibers (Novak et al., 2001; Devigili
et al., 2008; Hovaguimian and Gibbons, 2011). The diagnostic
yield of Devigili’s criteria can be increased by adding sudomotor
evaluation (Low et al., 2006; Thaisetthawatkul et al., 2013, 2014).
Therefore SFN was defined by the presence of all of the following:
(1) clinical signs suggestive of SFN and (2) at least one abnormal
test out of the following objective tests: ENFD, SGNFD, QSART,
or sympathetic adrenergic evaluation.
The SFN patients were further stratified into idiopathic SFN,
SFN secondary to other causes and SFN combined with large
fiber neuropathy.
Outcome Measures
The primary outcome measure was the correlation between ESC
at the feet and skin biopsies (ENFD and SGNFD) at the calf.
The secondary outcome measures were the correlations between
feet ESC and other continuous variables (QSART and symptom
scales).
STATISTICAL ANALYSIS
ENFD, SGNFD, and feet ESC have non-normal distribution.
Both ENFD and SGNFD were best approximated by a mixture
of 2 normal distributions, while ESC by a mixture of 3
normal distributions. ENFD, SGNFD, and ESC data were
normalized by adjusting for weight [e.g., normalized ESC
data = raw ESC/weight (kg)] (Figure 1). The adjustment
resulted in normal distribution for ESC, exponential distribution
for ENFD and Weibull distribution for SGNFD. Adjusted
data were used for correlation analysis if not indicated
otherwise.
Feet ESC in subjects who had abnormal biopsies were
compared to subjects with normal biopsies using non-parametric
Wilcoxon test.
The relationships between continuous variables were obtained
using Spearman’s rank correlation (ρ) coefficient. Least squares
(LS) models were used to evaluate the relationships between skin
biopsies and ESC as a dependent variable with age and sex as
model effect. LS models were calculated separately for ENFD
and SGNFD to minimize the effects of multiple comparisons.
Receiver operating characteristics (ROC) curves were calculated
to compare the diagnostic utility of ESC and QSART using ENFD
and SGNFD as a reference.
FIGURE 1 | Unadjusted raw ESC data (A) have non-normal distribution
and can be best-fitted by mixture of 3 normal distributions. ESC data
adjusted for weight (B) have normal distribution. (µ = 0.95, σ = 0.35).
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Power Calculations
Sincemultiple comparisons have been performed for correlations
calculations, the significance was adjusted using Bonferroni
corrections. For a hypothesis with a desired α = 0.05 and 15
comparisons, the Bonferroni-corrected α became equal to 0.003
(obtained by 0.05/15) which is required for the tests to be
significant. All statistical analysis were performed using JMP 12.0
(Cary, NC) statistical software.
RESULTS
Eighty-two consecutive patients evaluated for SFN were enrolled
in the study [(mean ± sd): age = 53.3 ± 17.3 years, men/woman
= 25/56, BMI = 27.9 ± 7.0 kg/m2]. None of our subject
experienced any complications of skin biopsies, autonomic
testing or any side effect associated with use of the Sudoscan
device. ENFD was obtained in 82 subjects, SGNFD in 70
subjects. In 12 subjects no sweat glands were identified in
the skin biopsies. ESC data from one subject were invalid
due motion artifact and 81 subjects were used for statistical
analysis.
SFN was identified in all subjects. ENFD was abnormal in
58 subjects, SGNFD in 25 subjects, QSART in 63 subjects, and
71 subjects had abnormal sympathetic adrenergic score that
evaluates blood pressure responses to the Valsalva maneuver and
tilt table.
The most common comorbidities were hypertension (n= 14)
and migraine (12). Disorders associated with SFN were identified
in 33 subjects (n), including diabetes (9), impaired glucose
tolerance (2), alcoholic neuropathy (2), thyroid disorder (4), B12
deficiency (2), Parkinson disease (2), elevated triglycerides (2),
metabolic syndrome (4), Sjögren syndrome (1), autoimmune
SFN (1), monoclonal gammopathy (2), end-stage renal disease
(1) and exposure to chemotherapy (1). Four patients in the mixed
autonomic and sensory SFN also had a large fiber mixed sensory-
motor length dependent neuropathy confirmed by abnormal
nerve conduction studies (NCS).
Idiopathic SFN, was identified in 48 (59%) patients with the
most disabling symptom being a distal burning sensation (14),
orthostatic symptoms (22), sphincter problems (6) and cold or
heat intolerance (4).
Figure 2 shows an example of ENFD and SGNFD from our
cohort. Subjects with abnormal ENFD (n = 58) had reduced feet
ESC (mean± sd: 0.88± 0.35µSiemens/kg) compared to subjects
with normal ENFD (n = 23, ESC = 1.17 ± 0.27 µSiemens/kg,
p < 0.0008 using Wilcoxon non-parametric test, Figure 3).
Subjects who had abnormal SGNFD (n = 25) had reduced feet
ESC (mean ± sd; 0.78 ± 0.3 µSiemens/kg) compared to subjects
with normal SGNFD (n = 41, ESC = 1.09 ± 0.34 µSiemens/kg,
p< 0.0003 using t-test, Figure 3).
Feet ESC correlated with ENFD and SGNFD at the calf
(Table 1, Figure 4). ESC did not correlate with QSART at the
foot (ρ = 0.2, p < 0.07 both unadjusted and ρ = 0.2, p < 0.06
both adjusted). QSART at the foot did not correlate with ENFD
(ρ = −0.008, p < 0.94 both unadjusted, ρ = 0.1, p < 0.37 both
adjusted) or SGNFD (ρ = −0.14, p < 0.26 both unadjusted and
FIGURE 2 | Representative examples of SGNFD (A) and ENFD (B).
Tissue processing for SGNFD and ENFD was done using bright-field
immunohistochemistry with anti-9.5 antibodies. The tissue sections were
counterstained with eosin. In Figure 1A, the arrows point to a sweat gland. In
Figure 1B, the arrows point to the epidermal-dermal junction and the
arrowheads point to epidermal nerve fibers. Bar = 50 microns. SGNFD, sweat
gland nerve fiber density; ENFD, epidermal nerve fiber density.
ρ= 0.006, p< 0.95 both adjusted). ENFD correlated with SGNFD
(ρ= 0.52, p< 0.0001, unadjusted data).
ESC did not correlate with subjective pain and autonomic
scales (Table 1). QSART at the foot did not correlate with the
pain (0–10) scale (ρ = −0.07, p < 0.48), the Neuropathic Pain
Symptom Inventory (ρ = −0.15, p < 0.17), the Neuropathy
Total Symptom Score-6 (ρ = −0.18, p < 01), or the Survey of
Autonomic Symptoms (ρ=−0.02, p< 0.84).
Feet ESC did correlated with hemoglobin A1C [ρ = −0.4,
p = 0.01, number of subjects (n) = 39]. ESC did not correlate
with folate (ρ=−0.09, p= 0.6, n= 31), B12 (ρ= 0.05, p= 0.78,
n= 37) or TSH (ρ= 0.22, p= 0.15, n= 43).
LS models showed significant effects of ENFD (p = 0.001),
but not of age (p = 0.25) or gender (p = 0.06) on ESC adjusted
by weight. LS models showed significant effects of SGNFD
(p = 0.001) and age (p = 0.0018) but not gender (p = 0.13) on
ESC adjusted by weight.
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FIGURE 3 | Comparison of ESC (mean ± se) in subjects with normal and abnormal skin biopsies using unadjusted raw ESC (A) and ESC data adjusted
for weight (B). Recommended threshold for normal range is ≥ 70 µSiemens (A) per the manufacturer of the device corresponding approximately to 0.93 µSiemens
per kg on adjusted ESC data (B). *p < 0.04; NS, not significant; **p < 0.0008; ***p < 0.0003. ESC, electrochemical skin conductance; SGNFD, sweat gland nerve
fiber density; ENFD, epidermal nerve fiber density.
TABLE 1 | Pairwise correlations between adjusted ESC and measured
variables.
Variable 1 P p-value
SGNFD ρ = 0.64, n = 66 = 0.0001
ENFD ρ = 0.73, n = 81 = 0.0001
Hemoglobin A1c ρ = −0.4, n = 39 = 0.01
NPSI −0.05 = 0.67
Pain scale (0–10) −0.02 = 0.88
NTSS-6 −0.05 = 0.67
SAS 0.17 = 0.13
ESC, electrochemical skin conductance at the feet adjusted for weight. Pearson
correlation (r) and Spearman’s rank correlation (ρ) coefficients have been used for
data with normal and non-normal distributions, respectively. SGNFD, sweat gland
nerve fiber density; ENFD, epidermal nerve fiber density; NPSI, the Neuropathic Pain
Symptom Inventory; NTSS-6, the Neuropathy Total Symptom Score-6; SAS, the Survey
of Autonomic Symptoms.
ROC curves (Figure 5) were significant for adjusted ESC using
ENFD (Figure 5A) and SGNFD (Figure 5B) but not for QSART
using ENFD (Figure 5C) or SGNFD (Figure 5D).
DISCUSSION
In this functional-pathological study, ESCwas compared to nerve
fiber densities obtained from skin biopsies. The main result of
the study is that feet ESC is reduced in subjects with abnormal
ENFD and SGNFD and that the reduction in ESC is proportional
to the reduction of skin fibers. These findings indicate that
reduced ESC may reflect axon loss. The correlation is remarkable
considering the fact that ESC is measured at the soles of the
feet while the biopsy was done at the calf. Ideally in a direct
histologic-functional correlation both tests should be performed
at the same location. However, both tests were implemented
using recommended standards. ENFD and SGNFD have never
been validated on the soles of the feet and ESCmeasurements are
currently only possible at the soles and palms.
It can be argued that the significant correlations between
ESC and skin biopsies could be driven by a few outliers as the
unadjusted data implies. However, adjusted data have normal
distribution and non-normal outliers were eliminated (compare
Figures 1A, 3A, 4A with Figures 1B, 3B, 4B). Using adjusted
ESC data may explain differences from previous studies. Our
subjects were heavier (man BMI = 27.8 kg/m2) than those in
previously reported studies (BMI< 25 kg/m2) (Vinik et al., 2015).
In our study, the ESC data were adjusted by weight and
this adjustment resulted in normal ESC distribution indicating
that ESC is affected by subjects’ weight. Since the measurement
occurs in the standing position, the weight-dependency could be
due to the sensitivity of the stainless steel electrodes to pressure
that is proportional to weight; alternatively, ESC depends on
the size of the foot since heavier people may have larger feet.
Both alternatives can be tested, by either eliminating differences
in pressures by obtaining ESC in the supine position and/or
by measuring the foot volume. Our data also suggest that
the adjusted threshold for normative value is equal to 0.93
µSiemens/kg.
Previous studies using Sudoscan device were predominantly
focused on diabetic patients (Smith et al., 2014; Vinik et al., 2015)
while our study uses a more heterogenous population. ROC
analysis for ESC obtained in our study (0.74, 0.767 for ENFD and
SGNFD as a reference) were almost identical to those obtained
in a previous study for ESC and ENFD (0.761, 0.752) using Utah
Early Neuropathy Score as a reference (Smith et al., 2014). The
most common diagnosis in our group was idiopathic SFN (59%)
suggesting that our results are not linked to a particular disorder
but may be applicable in general for evaluating small skin fibers.
ESC correlated better with sensory ENFD than with
sudomotor SGNFD density. This might be surprising since it is
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FIGURE 4 | Correlations of electrochemical skin conductance with ENFD and SGNFD. Each dot represents one patient. Panels (A,B) show raw data, while
panels (C,D) depict data adjusted for weight. ESC, electrochemical skin conductance; µS, microSiemens; ENFD, epidermal nerve fiber density; SGNFD, sweat gland
nerve fiber density.
thought that ESC measures chloride ion current produced by
sweat glands. There are several possible explanations for this
finding: (1) ESC response may also be dependent on the small
sensory fibers; (2) Small sensory fibers degenerate along with the
sudomotor fibers, hence the correlations are not causative; (3)
SGNFD also measures in part small sensory fibers. A cardinal
assumption made is that SGNFD evaluates sudomotor fibers.
However, the marker used for fiber staining, namely PGP 9.5, is
pan-axonal and it does not differentiate fiber subtypes. Although
occasionally CGRP-positive sensory fibers can be detected within
sweat glands, much denser innervation of sweat glands occurs
from sudomotor sympathetic fibers (Wang et al., 2011). Hence
it is unlikely that sensory innervation contributes significantly to
SGNFD. Nevertheless, studies with enrollment of subjects with
selective involvement of either small sensory or sudomotor fibers,
for example subjects with congenital absence of sweat glands
may clarify if ESC reflects the function of small sensory fibers,
sudomotor fibers or both.
Limitations of the Study
Referral bias and a relatively small number of patients could
affect results. In spite of our best efforts, hemoglobin A1C was
obtained in only 39 subjects. Therefore although the significant
correlation between ESC and hemoglobin A1C is promising,
it needs to be confirmed by larger studies. Lack of correlation
of ESC with hemoglobin A1C in previous studies can be
explained by using unadjusted ESC data. In diabetic subjects
ESC correlates with NCS (Selvarajah et al., 2015) which measure
large fibers. Than a question arises if ESC may be influenced
in part by function of large fibers. Since the current study did
not evaluate NCS, the impact of large fibers on ESC should
be addressed in future studies. Another limitation of the study
is the use of 1 to 2 sweat glands for SGNFD and that no
sweat glands were identified in 12 subjects. An increased yield
could be achieved by using a larger diameter biopsy punch or
deeper biopsies. However this increases the invasiveness of the
procedure which may result in biopsy complications. Finally,
it remains to be determined how accurately ESC can track
changes in small nerve fibers longitudinally (Selvarajah et al.,
2015).
CONCLUSIONS
This study demonstrates a correlation between structural (ENFD
and SGNFD) and functional (ESC) tests. The main strengths
of our study are: (1) its prospective nature, (2) the favorable
distribution of study subjects compared to typical SFN patient
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FIGURE 5 | Receiver operating characteristics (ROC) curves for ESC using ENFD (A) and SGNFD (B) as a reference. Panels (C,D) show ROC of
unadjusted QSART using ENFD and SGNFD, respectively. ROC = 0.6, p < 0.26 and ROC = 0.5, p < 0.46 for QSART adjusted for weight for ENFD and SGNFD,
respectively. ENFD and SGNFD have been adjusted for weight in all calculations.
populations and (3) the effective blinding of the data processing
since ENFD and SGNFD were analyzed in a separate institution.
Longitudinal studies may be better suited to assess the
accuracy of ESC in the detection of axon loss.
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